MedicaidPrior AuthMedium impact
Rituxan Hycela™ (rituximab/hyaluronidase) (Revised)
Humana·IN · Oncology, Hematology·Medicaid
Effective date
Jul 1, 2024
We identified it
Jun 24, 2026
Summary
Humana Medicaid Indiana has updated prior authorization criteria for Rituxan Hycela (rituximab/hyaluronidase) subcutaneous solution for treating chronic lymphocytic leukemia, follicular lymphoma, and diffuse large B-cell lymphoma. All patients must have prior treatment with intravenous rituximab before approval for the subcutaneous formulation.
Action Required
Immediately: Billing and clinical staff must verify all Rituxan Hycela prior authorization requests include documentation of prior intravenous rituximab treatment and meet specific diagnosis-based criteria. Update prior auth request templates to include required prior IV rituximab documentation. Requests without this documentation will be denied.